Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Current Assets (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Current Assets data on record, last reported at $10.5 million in Q3 2025.

  • For Q3 2025, Current Assets fell 23.46% year-over-year to $10.5 million; the TTM value through Sep 2025 reached $10.5 million, down 23.46%, while the annual FY2024 figure was $11.6 million, 34.74% down from the prior year.
  • Current Assets reached $10.5 million in Q3 2025 per GANX's latest filing, up from $9.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $47.4 million in Q1 2021 and bottomed at $9.3 million in Q2 2025.
  • Average Current Assets over 5 years is $22.9 million, with a median of $18.5 million recorded in 2024.
  • Peak YoY movement for Current Assets: soared 319.7% in 2021, then crashed 49.8% in 2025.
  • A 5-year view of Current Assets shows it stood at $37.7 million in 2021, then crashed by 44.09% to $21.1 million in 2022, then dropped by 15.71% to $17.8 million in 2023, then crashed by 34.74% to $11.6 million in 2024, then fell by 9.35% to $10.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $10.5 million in Q3 2025, $9.3 million in Q2 2025, and $11.2 million in Q1 2025.